Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.

by Yi Yu, Ronald E Savage, Sudharshan Eathiraj, Justin Meade, Michael J Wick, Terence Hall, Giovanni Abbadessa, Brian Schwartz
Published 2015-01-01

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.

by Terence G Hall, Yi Yu, Sudharshan Eathiraj, Yunxia Wang, Ronald E Savage, Jean-Marc Lapierre, Brian Schwartz, Giovanni Abbadessa
Published 2016-01-01

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

by Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker, Erin Hertlein, John C. Byrd
Published 2020-01-01